Novo Nordisk’s Refixia has come out on top in a head to head study assessing its effect in patients with the bleeding disorder haemophilia B against Swedish Orphan Biovitrum’s recombinant factor IX-Fc fusion protein (rFIXFc).
Read More
Novo Nordisk says it expects to launch its long-acting haemophilia B drug Refixia in the European Union in the fourth quarter of this year after receiving a green light from regulators.
Read More
Six new medicines, including three orphan drugs for rare diseases, have been backed for European Union approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Read More
